Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Ovarian Neoplasms 9Neoplasms 9Carcinoma, Non-Small-Cell Lung 9Lung Neoplasms 7Glioblastoma 7Colorectal Neoplasms 6Gliosarcoma 5Neoplasm Metastasis 4Colonic Neoplasms 4Breast Neoplasms 4Brain Neoplasms 4Rectal Neoplasms 3Fallopian Tube Neoplasms 3Carcinoma, Renal Cell 3Advanced Solid Tumor 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solitary Fibrous Tumor, Pleural 2Sarcoma, Alveolar Soft Part 2Sarcoma 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Oligodendroglioma 2Mesothelioma, Malignant 2Melanoma 2Leukemia, Myeloid, Acute 2Carcinoma, Ovarian Epithelial 2Breast Neoplasms, Male 2Astrocytoma 2Waldenstrom Macroglobulinemia 1

Interventions

pembrolizumab 1motesanib diphosphate 1lenvatinib 1cediranib 1Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Thyroid cancer, Hurthle cell × cediranib × Clear all
NCT01208051 2021-07-15

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
127 enrolled 18 charts
EndocrineHead & Neck

Thyroid cancer, Hurthle cell, Thyroid Cancer, Papillary, Adenocarcinoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡